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Abstract
We present the case of a 71 year old man with recurrence of a Gastro Intestinal Stromal Tumour (GIST) at the
gastrojejunal anastomosis eight years following partial gastrectomy for a very small primary gastric GIST. He
presented acutely on both occasions with haemodynamic shock secondary to massive haematemesis. During his
initial presentation in 2001, an emergency laparotomy was performed, demonstrating a pre-pyloric ulcerative
lesion. The histopathology was in keeping with a diagnosis of a gastric GIST with a < 2 cm tumour, with <5 mitosis
per 50/HPF, no signs of necrosis and invasion limited to the mucosa. Eight years later the same patient presented
with a similar clinical picture of haemodynamic instability secondary to haematemesis. Emergency endoscopy
showed an irregularly shaped elevated lesion on the gastrojejunostomy line suggestive of recurrence. He
subsequently underwent completion gastrectomy and the histology revealed a 0.8 cm GIST tumour composed of
spindle cells with <5 mitosis per 50/HPF, tumor invasion into the submucosa and positive expression of c-kit and
SMA. The patient remains recurrence free 18 months post surgery. The literature suggests that tumour size, mitotic
rate and tumour site are the most important predictive factors of recurrence. Additional features such as the pre-
sence of necrosis, local tumour invasion and positive resection margins, can also influence recurrence rates. In this
case the lesion was a gastric GIST, very small (<2 cm), had low proliferation rate (<5 mitosis/HPF), lacked necrosis
and was limited to the mucosa. Recurrence of such a primary GIST at the anastomotic line, eight years after initial
resection has never been demonstrated among review of several thousand primary GISTs. This case highlights how
even the most innocent GISTs can never be described as truly benign.
Background
Gastrointestinal stromal tumours (GISTs) are the most
common form of mesenchymal tumours found in the
gastrointestinal (GI) tract. GISTs most commonly occur
in the stomach and small intestine but can also be
found in smaller numbers in the colon, rectum and
oesophagus [1]. Many GISTs are asymptomatic and are
discovered incidentally, however over half of gastric
GISTs present with signs of GI bleeding and anaemia
with a smaller proportion presenting with abdominal
pain or as an abdominal mass [2]. Histologically, GISTs
are often composed of spindle shaped cells with a smal-
ler number dominated by epithelioid or a mixture of
both spindle and epithelioid cells [3,4]. Although GISTs
are a relatively newly discovered cancer, there has been
increased attention due to the development of effective
targeted agents [5]. Tyrosine kinase inhibitor (TKI) ther-
apy with imatinib has significantly prolonged progres-
sion free survival in advanced unresectable disease with
over 80% of advanced GIST patients benefiting [5].
Primary GISTs have uncertain malignant potential and
the long term prognosis of GIST has been challenging
for clinicians and pathologist alike. Large multi centre
studies on primary GISTs have lead to the development
of prognostic scoring systems based on tumour histo-
pathology [6,7]. Within these studies, several thousand
primary GIST cases have been reviewed and none of
them have demonstrated late local recurrence of a very
small (<2 cm), low mitotic rate (<5 mitosis/50 High
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Power Field (HPF)) gastric tumour [3,4,6-9]. For this
reason these tumours have been described as essentially
benign [7,10]. In this report we discuss recurrence in
such a case.
Case Presentation
A 71 year old man with signs of syncope and haemor-
rhagic shock secondary to massive haemetemesis was
referred for emergency treatment and investigation to
the 1st Department of Surgery, University of Athens
Medical School in 2009. Eight years earlier the same
patient, who had a known history of gastric ulcers, pre-
sented with a similar clinical picture to a different surgi-
cal unit. On admission he showed signs of haemorrhagic
shock with a haemoglobin level (Hg) of 7 g dL. Emer-
gency upper GI endoscopy was unable to identify the
source of bleeding due to large volumes of blood in the
stomach. Surgical treatment with a laparotomy was
decided and the intraoperative findings demonstrated an
acute gastric hemorrhage secondary to a massive propy-
loric ulcerative lesion. Resection of the lesion was
decided and a distal gastrectomy and Billroth II recon-
struction performed. The subsequent histology revealed
a <2 cm gastrointestinal stromal tumour, with a mitotic
rate of < 5 mitosis/50 per HPF, lacking necrosis and
localized to the gastric mucosa. The patient made an
uneventful recovery and was discharged eleven days
post surgery. The patient was reviewed over the follow-
ing two years and repeat endoscopies failed to reveal
any signs of recurrence. The patient subsequently
declined further surveillance and follow up.
At his readmission in 2009 the patient was primarily
treated conservatively due to his hemodynamic instabil-
ity. After successful resuscitation, an emergency upper
GI endoscopy was performed which revealed an irregu-
larly shaped elevated lesion on the gastrojejunostomy
line and a thrombus at the center of the lesion. The
hemorrhagic lesion was situated along the posterior ana-
stomotic suture line. Multiple biopsies were performed
and a definitive endoscopic haemostasis was obtained.
Preoperative staging computed tomography (CT)
showed no lymphadenopathy or hepatic metastasis and
as the patient’s performance status was otherwise excel-
lent, the decision for a second operation was deemed
favorable. The patient went on to have a successful com-
pletion gastrectomy with regional lymphadenectomy and
the continuity of the gastrointestinal tract was main-
tained through the Roux-en-Y method. It is important to
note that lymphadenectomy is not routinely performed
in GIST as metastatic spread rarely occurs through the
lymphatic system. However the unusual presentation of
the case created uncertainty over the malignant potential
of the tumour and the experienced surgeons deemed
lymphadenectomy the most appropriate measure in this
instance. Histological review of the specimen showed
macroscopically an ulcerative lesion on the suture-line,
measuring 0.8 cm in diameter. The cut surface was gray
with a rubbery consistency. Microscopically, it was a gas-
trointestinal stromal tumor (figure 1), composed of spin-
dle cells with mild to moderate nuclear pleomorphism.
The stroma focally had a myxoid appearance. The tumor
invaded into the submucosa, showed no signs of necrosis
and had positive expression of c-kit (figure 2), focally
positive expression of SMA, and negative expression of
CD34. The postoperative course was uneventful, and the
patient shows no evidence of recurrence 1 year and 6
months after the last surgery. It is noteworthy to mention
that GIST in this patient occurred sporadically and that
there were no clinical findings suggestive of familial
GIST which can be seen in patients with neurofibramato-
sis type 1 (NF1) or in the Carney-Stratakis dyad.
Conclusions
The significant majority of mesenchymal tumors of the
stomach are believed to derive from the interstitial cells
of Cajal, the gut pacemaker cells [11]. Since this cell
expresses CD117, it was assumed that expression of
CD117 by GIST was evidence of origin from that cell
type [11]. GIST can occur anywhere in the gastrointest-
inal (GI) tract but most commonly occurs in the sto-
mach. The median age of presentation is 60 years with
no significant differences between males and females
[12]. The presentation varies according to tumour site
with GI bleeding and abdominal pain being most com-
mon [12]. Endoscopy with biopsy is used to identify the
tumour with the definitive diagnosis depending on his-
tological and immunohistochemical analysis. GISTs
show a wide range of histologic appearances but are
broadly divided into spindle and epithelioid cell types.
In general, the risk of malignancy is greater in
Figure 1 Gastric GIST in H-E stain (×20).
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epithelioid tumors than in spindle-celled neoplasms
[11,12]. The most important immunohistochemical mar-
kers of GISTs are expression of KIT (CD117), which is
found in over 90 percent of GISTs, and CD34 which
occurs in over 80 percent [11]. SMA is demonstrable in
about 25 percent and a smaller number of GISTs (3% to
5%) have mutations in platelet derived growth factor
receptor alpha (PDGFRA) instead [11]. Imatinib, a tyro-
sine kinase (TKI) inhibitor, antagonizes the effects of
the KIT and PDGFRA proteins and has revolutionized
the treatment of advanced and unresectable GISTs [5].
There is growing evidence that responsiveness to TKI
inhibitors is dependent on the type and site of mutation
with deletions appearing to be more aggressive than
point mutations and exon 9 mutations showing less
responsive to imanitib therapy than exon 11 lesions [5].
Primary GISTs have the potential for curative treat-
ment, with surgical resection the first line option for all
resectable non metastatic tumours. The overall 5 year
survival rate for resectable GISTs has been shown to
range from 46% to 78.5% [3,4]. However, predicting the
recurrence rate of primary resectable GISTs has been
very challenging. Over the past decade there have been
several high profile risk stratification tools for predicting
recurrence rates. The National Institute for Health
(NIH) and the National Comprehensive Cancer Network
(NCCN) has developed risk schemes for primary GIST
tumours [6,7,10]. The American Joint Committee on
Cancer (AJCC) has created a similar scheme but also
incorporate advanced and metastatic GISTs [13]. The
latest risk scheme has recently been published in the
seventh edition of the international union against cancer
(UICC) where a novel classification and staging system
using TNM is proposed [14].
The NIH risk scheme originally developed in 2002 by
a consensus conference of experts was based on the
tumour size and mitotic rate - subdividing GIST into
very low risk (tumour < 2 cm, < 5 mitosis/50HPF), low
risk (tumour 2-5 cm, < 5 mitosis/50HPF), intermediate
risk (tumour 5 cm-10 cm, < 5 mitosis/50HPF or tumour
< 5 cm and 6-10 mitosis/50HPF) and high risk (tumour
> 5 cm, >5 mitosis/50HPF or tumour >10 cm and any
mitotic rate) [6]. This prediction scheme was later vali-
dated with large population studies on GISTs. Nillson
et al reviewed 288 patients with primary GIST and
reported no recurrence in the very low risk group and a
1.9% recurrence in the low risk group [8]. Tryggvason
et al performed a similar study and also demonstrated
no recurrence in the very low risk group [9]. This risk
stratification was further expanded by Miettinen and
Lasota by including tumour site and this system was
adopted by the NCCN [7,10]. Gastric GISTs had the
lowest rate of recurrence with the highest rates in duo-
denal and rectal GISTs. In the largest ever series of
GIST patients (actual data for over 1900 GIST patients)
Miettinen and Lasota incorporated mitotic rate, tumour
size and tumour location as predictors for tumour
recurrence [7]. In the lowest risk group, tumour size
<2 cm and < 5 mitosis/50HPF, there was no reported
recurrence of GIST from any gastrointestinal site and
this group was essentially considered benign. Tumour
size <5 cm and < 5 mitosis/50 HPF (NIH very low risk
score) carries a 1.9% risk of recurrence from gastric
GIST increasing to 8.3% and 8.5% for duodenal and rec-
tal GIST respectively. The TNM system proposed by
the UICC applies a similar system to Miettinen and
Lasota and categorizes tumors into four major T-cate-
gories and corresponding UICC stages. The main pur-
pose of the TNM system is to produce a more
standardized surgical and oncological treatment for
patients with GIST. The usefulness of this system will
become evident with future clinical studies.
There have been subsequent studies and case reports
documenting late GIST recurrence with metastasis from
small (>2 cm but < 5 cm) tumours but no reported
cases, from our literature review, of local recurrence of
a very small (<2 cm), < 5 mitosis/50HPF, gastric GIST
[15]. Additional risk factors associated with recurrence
include presence of necrosis, infiltration of neighbouring
structures, high cellularity, serosal invasion, high vascu-
larity and positive tumour margins [12]. The original
primary GIST in this report was located in the stomach,
very small (< 2 cm), < 5 mitosis/50HPF, showed no
signs of necrosis, was localised to the mucosa and had
negative tumour margins.
There are several plausible hypotheses for tumour
recurrence in this instance. Despite the fact that the his-
topathological specimen resected was R0 there may still
have been some local infiltration of the tumour margin.
In addition there are several studies which highlight the
risk of tumour recurrence with intraoperative tumour
Figure 2 Gatric GIST/C-kit immunoexpression (×40).
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rupture or laceration [16]. Although this was not
reported at the time of surgery it would be a reasonable
explanation for recurrence of such a low risk GIST.
Multiple sporadic GISTs have been described in patients
who do not have germline mutations in KIT/PDGFRA
or neurofibromatosis [17]. In this instance there would
be development of an independent, potentially different
histopathogically, GIST [17]. Unfortunately the original
specimen is no longer available for further comparative
analysis and this theory could not be further
investigated.
According to the literature recurrence of GIST is
dependent on tumour size, mitotic rate and tumour site,
with additional factors such as necrosis, local invasion
and tumour free margins influencing recurrence also. In
the current case, the mass was very small, located in the
stomach, exhibited very low mitotic activity, showed no
signs of necrosis and was limited to the mucosa. Recur-
rence of such a GIST tumour on the suture line eight
years after resection presents a previously undocumen-
ted case and demonstrates that even the most subtle
GISTs can never be considered as truly benign.
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